Neogenomics, Inc.
NEO
$16.06
$0.221.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.21% | 11.09% | 10.56% | 11.90% | 10.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.21% | 11.09% | 10.56% | 11.90% | 10.23% |
| Cost of Revenue | 5.08% | 11.62% | 12.75% | 15.50% | 13.55% |
| Gross Profit | 19.54% | 10.40% | 7.88% | 7.43% | 6.02% |
| SG&A Expenses | -5.15% | 0.98% | 2.44% | 6.98% | 15.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.01% | 5.82% | 8.20% | 11.60% | 14.42% |
| Operating Income | 65.09% | 29.80% | 18.40% | -7.95% | -51.81% |
| Income Before Tax | 103.99% | 31.49% | 23.08% | -47.85% | -140.92% |
| Income Tax Expenses | 43.09% | -277.44% | -214.05% | 593.33% | -93.07% |
| Earnings from Continuing Operations | 104.96% | 34.01% | 35.52% | -53.28% | -141.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 104.96% | 34.01% | 35.52% | -53.28% | -141.88% |
| EBIT | 65.09% | 29.80% | 18.40% | -7.95% | -51.81% |
| EBITDA | 163.09% | 85.58% | 35.35% | -68.21% | -3,167.07% |
| EPS Basic | 104.91% | 34.94% | 36.27% | -51.58% | -138.92% |
| Normalized Basic EPS | 64.74% | 27.04% | 12.97% | -34.28% | -66.75% |
| EPS Diluted | 104.91% | 34.94% | 36.27% | -50.93% | -134.93% |
| Normalized Diluted EPS | 65.05% | 27.04% | 12.97% | -34.28% | -66.75% |
| Average Basic Shares Outstanding | 1.31% | 1.41% | 1.17% | 1.15% | 1.22% |
| Average Diluted Shares Outstanding | 2.25% | 1.41% | 1.17% | 1.15% | 1.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |